Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AT 02

Next Previous
Drug Profile

AT 02

Alternative Names: AT-02

Latest Information Update: 10 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Attralus; University of Tennessee
  • Developer Attralus
  • Class Immunoglobulin fusion proteins; Monoclonal antibodies; Peptide fragments; Recombinant fusion proteins
  • Mechanism of Action Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Amyloidosis

Most Recent Events

  • 04 Nov 2025 Phase-I/II clinical trials in Amyloidosis (IV), prior to November 2025
  • 04 Nov 2025 Efficacy data from a phase I/II trial in Amyloidosis released by Attralus
  • 12 Nov 2024 AT 02 receives Orphan Drug status for Amyloidosis in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top